NYSE:MRK - Merck & Co., Inc. Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$70.42 +0.05 (+0.07 %)
(As of 09/19/2018 08:00 AM ET)
Previous Close$70.37
Today's Range$69.89 - $70.90
52-Week Range$52.83 - $70.94
Volume6.80 million shs
Average Volume10.81 million shs
Market Capitalization$188.68 billion
P/E Ratio17.69
Dividend Yield2.74%
Beta0.81
Merck & Co., Inc. logoMerck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus treatment for dogs and cats; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. Merck & Co., Inc. has collaborations with Pfizer Inc., AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., IO Biotech, Premier Inc., Cue Biopharma, Inc., and Foundation Medicine, Inc. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:MRK
CUSIP58933Y10
Phone908-740-4000

Debt

Debt-to-Equity Ratio0.61
Current Ratio1.33
Quick Ratio1.04

Price-To-Earnings

Trailing P/E Ratio17.69
Forward P/E Ratio16.49
P/E Growth2.41

Sales & Book Value

Annual Sales$40.12 billion
Price / Sales4.73
Cash Flow$5.7533 per share
Price / Cash12.24
Book Value$12.69 per share
Price / Book5.55

Profitability

EPS (Most Recent Fiscal Year)$3.98
Net Income$2.39 billion
Net Margins3.67%
Return on Equity32.68%
Return on Assets13.02%

Miscellaneous

Employees69,000
Outstanding Shares2,696,190,000
Market Cap$188.68 billion

Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. declared a quarterly dividend on Tuesday, July 24th. Shareholders of record on Monday, September 17th will be given a dividend of $0.48 per share on Friday, October 5th. This represents a $1.92 annualized dividend and a dividend yield of 2.73%. The ex-dividend date is Friday, September 14th. View Merck & Co., Inc.'s Dividend History.

How will Merck & Co., Inc.'s stock buyback program work?

Merck & Co., Inc. announced that its board has approved a stock repurchase plan on Saturday, December 2nd 2017, which authorizes the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's board of directors believes its shares are undervalued.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) issued its quarterly earnings data on Friday, July, 27th. The company reported $1.06 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.03 by $0.03. The firm earned $10.47 billion during the quarter, compared to analyst estimates of $10.28 billion. Merck & Co., Inc. had a return on equity of 32.68% and a net margin of 3.67%. The business's quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.01 earnings per share. View Merck & Co., Inc.'s Earnings History.

When is Merck & Co., Inc.'s next earnings date?

Merck & Co., Inc. is scheduled to release their next quarterly earnings announcement on Friday, October, 26th 2018. View Earnings Estimates for Merck & Co., Inc..

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. issued an update on its FY18 earnings guidance on Friday, July, 27th. The company provided earnings per share guidance of $4.22-4.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.24. The company issued revenue guidance of $42-42.8 billion, compared to the consensus revenue estimate of $42.12 billion.

What price target have analysts set for MRK?

17 analysts have issued 12-month price objectives for Merck & Co., Inc.'s stock. Their forecasts range from $58.83 to $77.00. On average, they anticipate Merck & Co., Inc.'s share price to reach $67.8553 in the next year. This suggests that the stock has a possible downside of 3.6%. View Analyst Price Targets for Merck & Co., Inc..

What is the consensus analysts' recommendation for Merck & Co., Inc.?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 4 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Merck & Co., Inc..

Are investors shorting Merck & Co., Inc.?

Merck & Co., Inc. saw a increase in short interest in August. As of August 15th, there was short interest totalling 21,898,123 shares, an increase of 19.5% from the July 31st total of 18,327,762 shares. Based on an average daily trading volume, of 7,806,651 shares, the days-to-cover ratio is presently 2.8 days. Approximately 0.8% of the company's stock are sold short. View Merck & Co., Inc.'s Current Options Chain.

Who are some of Merck & Co., Inc.'s key competitors?

Who are Merck & Co., Inc.'s key executives?

Merck & Co., Inc.'s management team includes the folowing people:
  • Mr. Kenneth C. Frazier, Chairman, CEO & Pres (Age 63)
  • Mr. Robert M. Davis, CFO & Exec. VP of Global Services (Age 51)
  • Dr. Roger M. Perlmutter, Exec. VP & Pres of Merck Research Laboratories (Age 66)
  • Mr. Adam H. Schechter, Exec. VP & Pres of Global Human Health (Age 53)
  • Ms. Rita A. Karachun, Principal Accounting Officer, Sr. VP of Fin. & Global Controller (Age 54)

Has Merck & Co., Inc. been receiving favorable news coverage?

News coverage about MRK stock has been trending somewhat positive on Wednesday, Accern reports. The research group rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Merck & Co., Inc. earned a news impact score of 0.18 on Accern's scale. They also assigned headlines about the company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for Merck & Co., Inc..

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.88%), Bank of New York Mellon Corp (1.43%), Northern Trust Corp (1.21%), Morgan Stanley (0.59%), Macquarie Group Ltd. (0.55%) and Boston Partners (0.54%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, C Robert Kidder, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Rita A Karachun, Rochelle B Lazarus, Sanat Chattopadhyay, Thomas H Glocer, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks. View Institutional Ownership Trends for Merck & Co., Inc..

Which major investors are selling Merck & Co., Inc. stock?

MRK stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Federated Investors Inc. PA, Point72 Asset Management L.P., American Century Companies Inc., Natixis, Schroder Investment Management Group, MUFG Securities EMEA plc and Nomura Holdings Inc.. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Adam H Schechter, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Rita A Karachun, Sanat Chattopadhyay, Thomas H Glocer, Weir Mirian M Graddick and Wendell P Weeks. View Insider Buying and Selling for Merck & Co., Inc..

Which major investors are buying Merck & Co., Inc. stock?

MRK stock was bought by a variety of institutional investors in the last quarter, including Senator Investment Group LP, Bank of Montreal Can, Janus Henderson Group PLC, Bank of New York Mellon Corp, Investec Asset Management LTD, Chevy Chase Trust Holdings Inc., Macquarie Group Ltd. and Glenmede Trust Co. NA. View Insider Buying and Selling for Merck & Co., Inc..

How do I buy shares of Merck & Co., Inc.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $70.42.

How big of a company is Merck & Co., Inc.?

Merck & Co., Inc. has a market capitalization of $188.68 billion and generates $40.12 billion in revenue each year. The company earns $2.39 billion in net income (profit) each year or $3.98 on an earnings per share basis. Merck & Co., Inc. employs 69,000 workers across the globe.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]


MarketBeat Community Rating for Merck & Co., Inc. (NYSE MRK)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  652 (Thanks for Voting!)
Underperform Votes:  689 (Thanks for Voting!)
Total Votes:  1,341
MarketBeat's community ratings are surveys of what our community members think about Merck & Co., Inc. and other stocks. Vote "Outperform" if you believe MRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel